Evidence map›Paper›PMID 27299887›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2017

A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.

Seiji Ito, Takeshi Sano, Junki Mizusawa, Daisuke Takahari, Hiroshi Katayama, Hitoshi Katai, Yoshiyuki Kawashima, Takahiro Kinoshita, Masanori Terashima, Atsushi Nashimoto and 3 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03229096 (Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis), which is not on this map. Cited by 77 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 3 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03229096 phase2unknown statusnot on this map

Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2017 to 2021Enrolled35ConditionsChemotherapy Effect, Chemotherapeutic Toxicity, Gastric CancerArmsApatinib plus XELOX
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  5. Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019
    Trial
  10. Trial
  11. Trial
  12. Therapeutic value of para-aortic lymph node dissection in gastric cancer with extensive lymph node metastasis: integrated analysis of three phase II trials (JCOG2212A).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  13. Article
  14. Safety, survival outcomes, and prognostic factors in conversion surgery for advanced gastric cancer: a sub-analysis of Japanese patients in the CONVO-GC-1 study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Practical management of oligometastatic gastric cancer.ESMO gastrointestinal oncology · 2024
    Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 1 country.

Seiji ItoDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. seito@aichi-cc.jp.
Takeshi SanoDepartment of Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Junki MizusawaJCOG Data Center, National Cancer Center, Tokyo, Japan.
Daisuke TakahariDepartment of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Hiroshi KatayamaJCOG Operations Office, National Cancer Center, Tokyo, Japan.
Hitoshi KataiGastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Yoshiyuki KawashimaDivision of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan.
Takahiro KinoshitaGastric Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan.
Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Atsushi NashimotoDepartment of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Mikihito NakamoriSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Hiroaki OnayaDepartment of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, Japan.
Mitsuru SasakoDivision of Upper Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan.
Japanese Foundation For Cancer Research · JPAichi Cancer Center · JPHyogo Medical University · JPHyogo Prefectural Cancer Center · JPJapan Clinical Cancer Research Organization · JPNational Cancer Center Hospital East · JPNiigata Cancer Center Hospital · JPSaitama Cancer Center · JPShizuoka Cancer Center · JPTokyo National Hospital · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer with extensive lymph node metastasis is commonly considered unresectable, with a poor prognosis. We previously reported the results of the use of cisplatin and S-1 as preoperative chemotherapy for gastric cancer with extensive lymph node metastasis; docetaxel, cisplatin, and S-1 (DCS) have now been investigated for the same purpose.

methodsPatients received two or three 28-day cycles of DCS therapy (docetaxel at 40 mg/m

resultsBetween July 2011 and May 2013, 53 patients were enrolled, of whom 52 were eligible. The clinical RR was 57.7 % [30/52, 80 % confidence interval 47.9-67.1 %, p = 0.89], and R0 resection was achieved in 84.6 % of patients (44/52). Common grade 3 or grade 4 adverse events during DCS therapy were leukocytopenia (18.9 %), neutropenia (39.6 %), and hyponatremia (15.1 %). The common grade 3 or grade 4 surgical morbidity was abdominal infection (10.2 %). The pathological RR was 50.0 % (26/52).

conclusionsPreoperative DCS therapy was feasible but did not show a sufficient RR. Preoperative cisplatin and S-1 therapy is still considered the tentative standard treatment for this population until survival results are known.

Indexed as

GastrectomyLymph Node ExcisionAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCisplatinCombined Modality TherapyDocetaxelDrug CombinationsFemaleFollow-Up StudiesHumansIntestinal NeoplasmsLymphatic MetastasisLymph NodesCisplatinDocetaxelDrug CombinationsOxonic AcidS 1 (combination)TaxoidsTegafurAdjuvant chemotherapyGastrectomyLymphatic metastasisStomach neoplasms

Identifiers

PMID27299887
OpenAlexW2436775948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.